OS and PFS in patients who achieved ≥VGPR and <VGPR. (A) PFS based on response after 2 cycles. ≥VGPR, n = 240; median PFS, 28 months; 95% CI, 22-31. <VGPR, n = 600; median PFS, 30 months; 95% CI, 27-32; P = .6. (B) PFS based on response after 4 cycles. ≥VGPR, n = 350; median PFS, 31 months; 95% CI, 27-35. <VGPR, n = 490; median PFS, 29 months; 95% CI, 26-31; P = .1. (C) PFS based on best response with first-line treatment. >VGPR, n = 552; median PFS, 33 months; 95% CI, 31-36. <VGPR, n = 288; median PFS, 22 months, 95% CI, 18-25; P < .001. (D) OS based on response after 2 cycles. ≥VGPR, n = 240; median OS, 78 months; 95% CI, 67-102. <VGPR, n = 600; median OS, 96 months; 95% CI, 80-104; P = .1. (E) OS based on response after 4 cycles. ≥VGPR, n = 350; median OS, 89 months; 95% CI, 72-105. <VGPR, n = 490; median PFS, 91 months; 95% CI, 77-102; P = .9. (F) OS based on best response with first-line treatment. ≥VGPR, n = 552; median OS, 102 months; 95% CI, 87-108. <VGPR, n = 288; median PFS, 77 months; 95% CI, 61-88; P = .003.